Levores

Levores Indications/Uses

levofloxacin

Manufacturer:

Novell Pharma

Distributor:

Averroes Pharma
Full Prescribing Info
Indications/Uses
Treatment of the following infections caused by Staphylococcus sp, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus hemolyticus, Enterococcus sp and Peptostreptococcus sp, Neisseria gonorrhoeae, Moraxella catarrhalis, Propionibacterium acnes, Escherichia coli, Citrobacter, Salmonella sp (excluding S. typhi or S. paratyphi), Shigella sp, Klebsiella sp, Enterobacter sp, Serratia sp and Proteus sp, Vibrio cholerae, Pseudomonas aeruginosa, Haemophilus influenzae, Acinetobacter sp and Campylobacter sp or Chlamydia trachomatis susceptible to levofloxacin: Pneumonia, chronic bronchitis, diffuse panbronchiolitis, bronchiectasis with infection and secondary infections in chronic respiratory tract diseases. Laryngopharyngitis, tonsillitis (peritonsillitis, peritonsillar abscess) and acute bronchitis. Pyelonephritis, cystitis, prostatitis, epididymitis, gonococcal urethritis and nongonococcal urethritis.
Intrauterine infection, cervicitis, uterine adnexitis and bartholinitis. Folliculitis (including acne pustulosa), furuncle, furunculosis, carbuncle, impetigo contagiosa, erysipelas, phlegmon, lymphangitis/lymphadenitis, suppurative paronychia (including felon), subcutaneous abscess, hydradenitis, acne conglobata, infectious atheroma and periproctic abscess.
Mastitis, (superficial) secondary infections in traumatic wounds, burns, operative wound, etc.
Cholecystitis and cholangitis.
Otitis externa, otitis media, sinusitis and suppurative sialadenitis. Blepharitis, hordeolum, dacryocystitis, conjunctivitis and tarsadenitis. Bacterial dysentery, infectious enteritis, salmonella enteritis and cholera. Periodontitis, pericoronitis and gnathitis.
Treatment of adults (more than or equal to 18 years) with mild, moderate and severe infections caused by susceptible strains of the designated microorganisms in the conditions listed as follows. Levores 5mg/ml Solution for Infusion is indicated when IV administration offers a route of administration advantageous to the patient (eg, patient cannot tolerate an oral dosage form). (See Dosage & Administration.)
Acute maxillary sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae or Moraxella catarrhalis.
Acute bacterial exacerbation of chronic bronchitis due to Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae or Moraxella catarrhalis.
Community-acquired pneumonia due to Staphylococcus aureus, Streptococcus pneumoniae, Legionella pneumophila or Mycoplasma pneumoniae.
Uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to Staphylococcus aureus or Streptococcus pyogenes.
Complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis or Pseudomonas aeruginosa.
Acute pyelonephritis (mild to moderate) caused by Escherichia coli. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected.
As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in